Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Process of Elimination

This article was originally published in Start Up

Executive Summary

Incontinence represents a significant unmet medical need for 20 million Americans that suffer from urge incontinence, and 13 million sufferers of stress incontinence. The market is large, growing, and approachable for small device companies--if they can get funding, that is.

You may also be interested in...

Situs Corp.

Only a third or less of the population that suffers from urge incontinence seeks treatment, and half of the patients that do discontinue treatment because of the unpleasant side effects of orally-administered drugs that are currently on the market. Situs Corp. hopes to improve upon the efficacy of these drugs and avoid side effects by delivering drug directly into the bladder. The company is developing both formulations of drugs for intravesical (in the bladder) delivery as well as a delivery device.

Genyx Medical Inc.

Genyx Medical Inc.'s initial product, Uryx, is a permanent urethral bulking agent for, for example, coughing or laughing.

Surx Inc.

Dissatisfied with current invasive and complicated surgical techniques for stress urinary incontinence (SUI), the founders of [Surx Inc.] believe they can offer a better approach with a minimally invasive outpatient procedure that uses low power radio frequency (RF) to shrink collagen on the pelvic floor, and return stretched tissues to their normal anatomical position. SUI affects some 6.5 million women in the US, and more than 18 million worldwide

Related Content


Related Companies

Related Deals

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts